| UHC Commercial Medical & Drug | Encelto® (Revakinagene Taroretcel-Lwey) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-08-01 |
| UHC Commercial Medical & Drug | Entyvio® (Vedolizumab) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-08-01 |
| UHC Commercial Medical & Drug | Intracanalicular and Intravitreal Corticosteroid Implants – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-08-01 |
| UHC Commercial Medical & Drug | Kebilidi® (Eladocagene Exuparvovec-Tneq) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-08-01 |
| UHC Commercial Medical & Drug | Off-Label/Unproven Specialty Drug Treatment – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-08-01 |
| UHC Commercial Medical & Drug | Reblozyl® (Luspatercept-Aamt) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-08-01 |
| UHC Commercial Medical & Drug | Skyrizi® (Risankizumab-Rzaa) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-08-01 |
| UHC Commercial Medical & Drug | Surgery of the Wrist or Thumb – Commercial and Individual Exchange Medical Policy | 2026-08-01 |
| UHC Commercial Medical & Drug | Susvimo® (Ranibizumab Injection) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-08-01 |
| UHC Medicaid Medical & Drug | Complement Pathway Inhibitors – Community Plan Medical Benefit Drug Policy | 2026-08-01 |